Sanofi (SNY)
| Market Cap | 113.30B -11.3% |
| Revenue (ttm) | 57.89B +11.0% |
| Net Income | 4.74B -54.2% |
| EPS | 1.94 -53.2% |
| Shares Out | 1.20B |
| PE Ratio | 24.53 |
| Forward PE | 9.40 |
| Dividend | $2.42 (5.08%) |
| Ex-Dividend Date | May 4, 2026 |
| Volume | 2,245,799 |
| Open | 47.48 |
| Previous Close | 47.47 |
| Day's Range | 47.28 - 47.88 |
| 52-Week Range | 39.07 - 52.68 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 53.48 (+12.44%) |
| Earnings Date | Oct 30, 2026 |
About SNY
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia ... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $53.48, which is an increase of 12.44% from the latest price.
News
Nurix, Sanofi Diverge — And One Breaks Out — On A Shocking Eczema Development
Shares of Nurix Therapeutics crashed Wednesday after Sanofi unexpectedly scrapped an experimental eczema drug that two were codeveloping.
Sanofi price target raised to EUR 86 from EUR 82 at Morgan Stanley
Morgan Stanley analyst Thibault Boutherin raised the firm’s price target on Sanofi (SNY) to EUR 86 from EUR 82 and keeps an Equal Weight rating on the shares. Published first…
Sanofi price target raised to EUR 90 from EUR 83 at Barclays
Barclays raised the firm’s price target on Sanofi (SNY) to EUR 90 from EUR 83 and keeps an Equal Weight rating on the shares.
Sanofi price target raised to EUR 80 from EUR 75 at RBC Capital
RBC Capital raised the firm’s price target on Sanofi (SNY) to EUR 80 from EUR 75 and keeps a Sector Perform rating on the shares. The company reported a significant…
Regeneron Q3 Revenue Rises 36%; Pipeline Advances, FDA Catalysts Ahead; Stock Up
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) reported a 36% year-over-year increase in third-quarter 2026 revenue to $5.116 billion, supported by strong commercial performance and higher Sanofi ...
Sanofi Q3 Earnings Call Highlights
Sanofi NASDAQ: SNY reported third-quarter 2026 sales growth of 14.3% at constant exchange rates, supported by continued demand for Dupixent, recently launched medicines and growth in rare diseases. Th...
Sanofi Q3 Earnings Call Highlights
Giants Costco, Sanofi, and SAP Raise Dividends by Over 10%Sanofi (NASDAQ:SNY) reported third-quarter 2026 sales growth of 14.3% at constant exchange rates, supported by continued demand for Dupixent, ...
Regeneron, Sanofi Surge As Dupixent Wallops Sales Forecasts
Regeneron stock popped Thursday after its Sanofi-partnered allergic conditions drug, Dupixent, easily beat third-quarter calls.
Sanofi Earnings Call Transcript: Q3 2026
Q3 sales grew 14.3% to €14.4B and business EPS rose 19.6%, prompting upgraded FY2026 guidance. Strategy prioritizes three therapeutic areas, disciplined M&A and R&D renewal to support growth beyond Dupixent’s LOE.[document-source]9[document-source][document-source]16[document-source]
Sanofi Earnings release: Q3 2026
Sanofi released its Q3 2026 earnings on October 30, 2026, summarizing the period's financial results.
Sanofi Earnings release: Q3 2026
Sanofi released its Q3 2026 earnings on October 30, 2026, summarizing the period's financial results.
Sanofi Slides: Q3 2026
Sanofi has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 30, 2026.
Sanofi Q3 Profit Climbs On Dupixent Growth; Raises FY26 Guidance; Stock Up
(RTTNews) - French pharmaceutical company, Sanofi SA (SNY, SNYNF, SAN.PA) reported higher third-quarter net profit and business net income, supported by double-digit sales growth driven by new medicin...
Sanofi reports Q3 business EPS EUR 3.55, up 22% reported
Business EPS was EUR 3.55, up by 19.6% at CER; 22.0% at actual exchange rates; IFRS EPS EUR 2.52. Reports net sales EUR 14.4B, up 16.2% reported and 14.3% at…
Sanofi expects FY26 sales to grow by low-teens percentage at CER
2026 guidance is upgraded: sales are expected to grow by a low-teens percentage at CER. Business EPS at CER is expected to grow by a mid-teens percentage. Published first on…
Novavax, Inc. Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial
Novavax, Inc. reported that on October 28, 2026 Sanofi Pasteur Inc. dosed the fifth patient in its Phase 3 influenza-COVID-19 combination vaccine trial in the European Union, utilizing the company's C...
Sanofi Q3 Net Profit, Business Profit Climb; Lifts FY26 Outlook
(RTTNews) - French drug major Sanofi SA (SNY, SNYNF, SAN.PA) reported Friday higher net profit and business net income in its third quarter, with strong sales growth. Further, the firm upgraded its fi...
Sanofi CEO Sets Sights on Deals to Drive Turnaround
The French drugmaker is moving to fill its medicine pipeline to prepare for the looming patent expiration of its bestselling product, Dupixent.
Novavax Gains $125 Mln Payment As Sanofi Begins Phase 3 Combination Vaccine Trial; Stock Up
(RTTNews) - Novavax, Inc. (NVAX) said it has earned a $125 million milestone payment following the initiation of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial in Europe, which is evalu...
Novavax earns $125M milestone as Sanofi launches Phase 3 vaccine trial
Novavax (NVAX) has earned a $125M milestone payment with the initiation of Sanofi’s (SNY) Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax’s COVID-19 vaccine, Nuvaxovid. Sanofi’s...
Sanofi agrees to settle antitrust case in US over diabetes drug Lantus
Sanofi has reached a tentative settlement to resolve long-running claims by drug wholesalers that the pharmaceutical company used an improper patent listing to suppress competition to its diabetes tre...
These French Companies Have Global Reach. The Stocks Are Bargains.
Some investors are looking beyond turmoil in France for companies that depend little on their domestic market.
Teva, Sanofi Report Sustained Duvakitug Benefits In Phase 2b IBD Study
(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) and Sanofi (SNY) announced positive long-term Phase 2b data for investigational duvakitug, showing sustained improvements in ulcerative colitis (...
Sanofi, ScionxBio enter collaboration, licensing agreement
ScionxBio has entered into a worldwide strategic collaboration and licensing agreement with Sanofi (SNY) to develop and commercialize extended exposure versions of certain Sanofi mRNA candidates by le...
ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics
CAMBRIDGE, England--(BUSINESS WIRE)--ScionxBio (the “company”, operating as a brand identity of Eleven Therapeutics Ltd. following a horizontal split) a privately held, preclinical-stage biotechnology...